Oggi inizia ASCO, uno dei congressi più importanti dedicati alla cura dei tumori. Senza pretendere di essere esaustivo (impossibile con oltre 6mila presentazioni), qui vi racconterò i principali progressi. Stay tuned! #ASCO24

#ENASymp24 Showcase your early-stage drug developments at ENA in Barcelona, and position your company as leaders to drive innovation in oncology research and treatment. Download the Prospectus today. event.eortc.org/ena2024/indust…

FabriceAndre Giant of Cancer Care 2024 for Translational Cancer Research

Loved this interview with Toni Choueiri, MD Dana-Farber in the The ASCO Post. Amazing to see the strength & fortitude he had to endure difficult circumstances & rise to become a leader in #medicine . So much of this piece resonated with me, but absolutely loved the quote below in

Getting ready to head to #ASCO2024 in a few hours. Just brushing up on my academic conference question 'best habits' from Dr. Glaucomflecken:
youtube.com/watch?v=Pbl9Zc…

Good luck @asco moderators! May you have the grace to pick the right microphone.

OncoAlert

Excited and honored to present our newest race and ethnicity analysis from RxPONDER looking at recurrence score gene axes scores.

Join us May 31st at the Rapid Oral session, details 👇🏼

#bcsm #ASCO24
Kevin Kalinsky, MD, MS

Alright! It’s that time of the year again. #ASCO24 is about to start. Here are our now classic rules of engagement. (Still don’t know the author to quote and credit). As usual Steven Vogl is exempt. @asco @oncoalert Nathan A. Pennell MD, PhD, FASCO Narjust Florez, MD, FASCO Dr. Estela Rodriguez Stephanie Graff, MD, FACP, FASCO Dr Sunil Verma Mike Thompson, MD, PhD, FASCO

Thank you for your time and expertise!

Recently l've seen a lot of narratives about how clinicians who advocate for their health & wellbeing (& that of others) are not committed to medicine.

Let's put this myth to rest. To protect our longevity in this field (along with patient safety), we must be well.

#ADC on the run🚀
ASCO #ASCO2024 is going to be massive this year 🤞

ADCs keep shortening the distance between oncology fields. The HER2-low experience in breast onc, the dual ADC in GU, the ADC combos tested in GI & thoracic onc, all expand our knowledge on these important drugs. Thanks to Ryan Flinn for this interview! ajmc.com/view/wave-of-a…

12 Ways to Reduce Your Cancer Risk

The European Code Against Cancer offers practical steps to lower your cancer risk:
OncoAlert ESMO - Eur. Oncology IARC Union for International #CancerControl #CancerPrevention

On our way to what promises to be a tremendous #ASCO24 , full of new drugs, new knowledge, new hopes. See you all in Chicago! ✈️

Antonio Giordano, MD PhD Glenn J. Hanna, M.D. Dana-Farber’s Breast Oncology Center Dana-Farber’s CCTI

Looking forward to attending with Jose Acevedo

Honored to present LBA1000 at ASCO. This advancement is a game-changer in oncology, offering new hope for patients. #BreastCancerAwareness #HER2Low #ADCTherapy

I fully support #GiuseppeCurigliano G Curigliano MD PhD for the ESMO - Eur. Oncology Presidency.
✅Passionate and dedicated researcher
✅Inspiring and motivating mentor
✅Committed to inclusivity, diversity and gender balance

#cancer is increasing worldwide and around 50% of cancers can be prevented! Here are 12 ways to reduce the risk of cancer by European Commission
ESMO - Eur. Oncology ASCO IARC Belgian Society of Medical Oncology BIG against BC Institut Jules Bordet Instituut ULB ComRecherche @H.U.B #screening #lifechanges

POSITIVE Trial

🔹️Young age is the most important key factor for the duration until pregnancy
🔹️Highest pregnancy rates with embryo/oocyte cryopreservation followed by transfer
🔹️Ovarian stimulation didn't affect prognosis in 41-mo mFU (yet too short)

OncoAlert

Phase 1 study of BL-B01D1 (izalontamab brengitecan) = bispecific ADC targeting EGFR–HER3, with a TOPO1i payload (Ed-04)

sciencedirect.com/science/articl…

Great to see this publication after the presentation at #ASCO23 . And so much data, really comprehensive supplementary information!

Check out Dr. Sara Tolaney Sara Tolaney Dana-Farber’s Breast Oncology Center & Dr. Hope Rugo Hope Rugo UCSF Helen Diller Family Comprehensive Cancer Ctr discussing #ASCO24 Noteworthy Abstracts in Breast Cancer

Full📽️on #VuMedi
👇
shorturl.at/ceKhy

#bcsm #breastcancer #mBC #TNBC